Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12881950 | 0.86 | NTRK1 (0.41) | NTRK1ADORA2AADORA2BMAP2K4HTR1A | |
| SCHEMBL8348438 | 0.85 | KIF11 (0.47) | ADORA2AADORA2BMAP2K4ALDH1A1SMN1; SMN2 | |
| SCHEMBL7213936 | 0.84 | GAA (0.43) | NTRK1ADORA2AADORA2BMAP2K4CYP1A2 | |
| SCHEMBL29585213 | 0.84 | GAA (0.43) | NTRK1ADORA2AADORA2BMAP2K4CYP1A2 | |
| SCHEMBL1696402 | 0.81 | JAK2 (0.55) | NTRK1HTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL7978106 | 0.81 | HTR1D (0.41) | NTRK1MAP2K4HTR1AHTR1DHTR1B | |
| SCHEMBL12867031 | 0.81 | NTRK1 (0.40) | NTRK1ADORA2AADORA2BMAP2K4CYP1A2 | |
| SCHEMBL18072218 | 0.80 | HTR1D (0.41) | NTRK1MAP2K4HTR1AHTR1DHTR1B | |
| SCHEMBL1696762 | 0.80 | FGFR1 (0.43) | MAP2K4HTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL8239834 | 0.78 | HTR1A (0.43) | NTRK1ADORA2AADORA2BMAP2K4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| EP-4233859-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3600287-B1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | NTRK1 184/4885ADORA2A 307/4885ADORA2B 350/4885 |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | NTRK1 2104/4885ADORA2A 51/4885ADORA2B 97/4885 |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | F12, TFPI, F11 | NTRK1 2268/4885ADORA2A 1843/4885ADORA2B 527/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | NTRK1 461/4885ADORA2A 4192/4885ADORA2B 4727/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | NTRK1 4672/4885ADORA2A 1437/4885ADORA2B 1990/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | NTRK1 1240/4885ADORA2A 132/4885ADORA2B 365/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | NTRK1 3778/4885ADORA2A 2258/4885ADORA2B 3452/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | NTRK1 1911/4885ADORA2A 3545/4885ADORA2B 2326/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | NTRK1 3186/4885ADORA2A 3640/4885ADORA2B 2789/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | NTRK1 4834/4885ADORA2A 1720/4885ADORA2B 1911/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | NTRK1 273/4885ADORA2A 3395/4885ADORA2B 4433/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | NTRK1 1922/4885ADORA2A 1635/4885ADORA2B 1822/4885 |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | NTRK1 341/4885ADORA2A 2767/4885ADORA2B 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.